A novel peptide antagonist for SATB1 in the immune response to Leishmania infection
Microbial Pathogenesis · 2026
DOI: 10.1016/j.micpath.2025.108191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Pathogenesis, 2026. Verfasst von Diksha Jawale und 1 weiteren Autor:innen. Beteiligte Einrichtung: Systems Medicine Laboratory, BRIC-National Centre for Cell Science, NCCS Complex, Ganeshkhind, SPPU Campus, Pune, 411007, India. Hauptthemen laut MEDLINE: Matrix Attachment Region Binding Proteins, Peptides, Leishmaniasis, Cutaneous. Die Arbeit nennt 70 Literaturangaben. Gefördert von: National Centre for Cell Science, India Ministry of Science & Technology Department of Biotechnology.
Abstract (Originalsprache)
Peptide-based therapies are emerging as powerful tools in the treatment of inflammatory and infectious diseases, offering high specificity, low toxicity, and minimal side effects. In this study, we identify Special AT-rich Binding Protein-1 (SATB1) as a novel immunotherapy target for cutaneous leishmaniasis (CL). As a global chromatin regulator, SATB1 is initially confined to the cytoplasm, but as infection progresses, it translocates to the nucleus, triggering Basic Helix-Loop-Helix Family Member E40 (Bhlehe40) - mediated Granulocyte-macrophage colony-stimulating factor (GM-CSF) production and inflammatory responses involving IL-6, IL-17, IL-23, and Sphingosine-1-phosphate (S1P). To restore immune balance, we strategically disrupt conserved residues Lysine (Lys) 29, Arginine (Arg) 32, Glutamic acid (Gln) 34, and Asparagine (Asn) 36 within SATB1's nuclear localization signal (NLS) using machine learning (ML) based peptide design approaches. Structural predictions, motif identification, and peptide library screening led to the selection of three peptide candidates (P1, P2, and P3) based on binding affinity and molecular interactions. Experimental validation identified P3 as the most effective peptide, successfully mitigating infection and re-establishing immune homeostasis in vitro and in vivo. This research underscores the potential of peptide-based therapeutics in developing targeted treatments for cutaneous leishmaniasis and other immune-related disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Systems Medicine Laboratory, BRIC-National Centre for Cell Science, NCCS Complex, Ganeshkhind, SPPU Campus, Pune, 411007, India.
- Systems Medicine Laboratory, BRIC-National Centre for Cell Science, NCCS Complex, Ganeshkhind, SPPU Campus, Pune, 411007, India. Electronic address: singhs@nccs.res.in.
Förderung
- National Centre for Cell Science
- India Ministry of Science & Technology Department of Biotechnology
Zitieren
APA
Jawale, D., & Singh, S. (2026). A novel peptide antagonist for SATB1 in the immune response to Leishmania infection. Microbial Pathogenesis. https://doi.org/10.1016/j.micpath.2025.108191
Vancouver
Jawale D, Singh S. A novel peptide antagonist for SATB1 in the immune response to Leishmania infection. Microbial Pathogenesis. 2026. doi:10.1016/j.micpath.2025.108191
BibTeX
@article{Jawale2026,
author = {Jawale, Diksha and Singh, Shailza},
title = {A novel peptide antagonist for SATB1 in the immune response to Leishmania infection},
journal = {Microbial Pathogenesis},
year = {2026},
doi = {10.1016/j.micpath.2025.108191}
}
EUVIMED